Korro Bio (KRRO) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Korro Bio (KRRO) has outperformed SIGA Technologies (SIGA) over the past year, gaining 93.9% versus a loss of 58.9%. Over five years, SIGA leads with a -71.9% price change compared with -95.7% for KRRO. SIGA Technologies is the larger company by market cap ($172.5 million vs $167.2 million), about 1.0 times the size, while Korro Bio is growing revenue faster (+181.5% vs -31.8%).
SIGA Technologies converts more of its revenue into profit, with a net margin of 24.6% versus -1834.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | SIGA |
|---|---|---|
| Share price | $12.18 | $2.40 |
| Market cap | $167.18M | $172.45M |
| 1-day change | -0.08% | -9.43% |
| YTD return | +52.06% | -60.72% |
| 1-year return | +93.95% | -58.90% |
| 5-year return | -95.67% | -71.90% |
| P/E ratio (TTM) | — | 240.00 |
| Forward P/E | — | 5.45 |
| EPS (TTM) | $-8.89 | $0.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.39M | $94.57M |
| Revenue growth (YoY) | +181.46% | -31.82% |
| Net income (latest FY) | $-117.26M | $23.28M |
| Gross margin | — | 68.59% |
| Operating margin | -1906.37% | 25.06% |
| Net margin | -1834.48% | 24.61% |
| 52-week high | $17.35 | $7.11 |
| 52-week low | $5.20 | $2.30 |
| Distance from 52-week high | -29.81% | -66.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +76.52% | +35.42% |
| Average volume | 186.03K | 617.60K |
| Shares outstanding | 13.73M | 71.86M |
| Employees | 58 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRRO has outperformed SIGA by 152.9 percentage points over the past year.
- SIGA Technologies is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
- Korro Bio grew revenue faster in its latest fiscal year (+181.46% vs -31.82%).
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
KRRO vs SIGA FAQ
Which is bigger, Korro Bio or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $172.45M compared with $167.18M for Korro Bio (KRRO).
Which stock has performed better over the past year, KRRO or SIGA?
KRRO returned +93.95% over the past 12 months, compared with -58.90% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Korro Bio and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.